Duke University School of Medicine
Naval Medical Center
American Board of Internal Medicine - Hematology
American Board of Internal Medicine - Oncology
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Mittendorf, E.A., Clifton, G.T., Holmes, J.P., Clive, K.S., Patil, R., Benavides, L.C., Gates, J.D., Sears, A.K., Stojadinovic, A., Ponniah, S., Peoples, G.E.; Cancer. 2012 May 15.See more >>
The GP2 peptide: a HER2/neu-based breast cancer vaccine.
Clive KS, Tyler JA, Clifton GT, Holmes JP, Ponniah S, Peoples GE, Mittendorf EA; J Surg Oncol. 2012-04-01.See more >>
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.
Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE; Ann. Oncol.. 2014-09-01.See more >>
American Society of Clinical Oncology